reneopharma.com (RPHM) Quarterly EPS earnings growth

Symbol and logo of brand Reneo Pharmaceuticals, Inc (RPHM)

Due to the suspension of trials, Reneo Pharmaceuticals (RPHM) has shifted to strict austerity measures, which has neutralized its operating leverage. The quarterly growth in earnings per share illustrates this decline, and the metric currently stands at 74.60. The company's revenues are based on investments prior to the market launch of mitochondrial therapies. Management is now systematically downsizing the corporate structure following the failed test, transparently allocating the remaining capital.

RPHM: Reneo Pharmaceuticals, Inc. Year-over-year earnings per one share growth for the last 12 months 07/04/2022 - 10/07/2024

Reneo Pharmaceuticals (RPHM) - metric breakdowns and financial figures

- share price and expert price forecast:
Initial company analysis:Reneo Pharmaceuticals
Flagship merchandise of Reneo Pharmaceuticals, Inc

Reneo Pharmaceuticals scientific partnerships in the field of myopathy treatment directly impact operating expenses and the pace of profit capitalization. The quarterly EPS gap dynamics reflect the percentage change in net income per share compared to the same period last year, allowing investors to assess the real efficiency of the business and avoid purchasing the asset at an emotional valuation peak.

Who Reneo Pharmaceuticals competes with

VRTX: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Alnylam Inc. (ALNY)|INSM (Insmed) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months UTHR (United Therapeutics Corporation)|Year-over-year net earnings per share growth for the last 12 months BMRN (BioMarin)|BBIO (BridgeBio Pharma) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth BGM (BGM Group Ltd)|COGT (Cogent Bio) - Year-over-year net earnings per share trend for the last twelve months|Xeris Biopharma - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months KROS (Keros Therapeutics)|ARCT: Quarterly EPS earnings growth|Eton Pharmaceuticals Inc (ETON) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Kamada Corp|FULC: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Abeona Therapeutics, Inc. (ABEO)|Year-over-year net earnings per share growth for the last 12 months Mereo BioPharma Group plc MREO|Year-over-year earnings per share growth for the last twelve months Protalix BioTherapeutics PLX|Quarterly EPS earnings growth Pliant Therapeutics PLRX|appliedtherapeutics.com - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months RNTX (Rein Therapeutics, Inc.)|GELS: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Aytu BioPharma, Inc. (AYTU)|CMMB (Chemomab Therapeutics Ltd) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months SRXH (SRx Health Solutions)|Year-over-year net earnings per share growth for the last 12 months PLRZ (Polyrizon Ltd)|AEZS - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Cyclo Therapeutics Inc. CYTH|Inozyme Pharma, Inc. (INZY) - Earnings per share growth in annualized terms for the last twelve months|COSCIENS Bio - Quarterly EPS earnings growth